Recursion Pharmaceuticals, Inc. $RXRX Shares Purchased by Handelsbanken Fonder AB

Handelsbanken Fonder AB boosted its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 20.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 88,700 shares of the company’s stock after purchasing an additional 15,100 shares during the period. Handelsbanken Fonder AB’s holdings in Recursion Pharmaceuticals were worth $449,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in RXRX. Brighton Jones LLC lifted its position in shares of Recursion Pharmaceuticals by 49.4% in the 4th quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock valued at $137,000 after acquiring an additional 6,699 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at $57,000. Cetera Investment Advisers raised its holdings in shares of Recursion Pharmaceuticals by 22.6% during the first quarter. Cetera Investment Advisers now owns 75,788 shares of the company’s stock worth $401,000 after acquiring an additional 13,955 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Recursion Pharmaceuticals by 15.5% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 76,730 shares of the company’s stock valued at $406,000 after buying an additional 10,272 shares during the last quarter. Finally, LPL Financial LLC grew its position in Recursion Pharmaceuticals by 15.6% in the first quarter. LPL Financial LLC now owns 425,090 shares of the company’s stock worth $2,249,000 after acquiring an additional 57,305 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Price Performance

Shares of Recursion Pharmaceuticals stock opened at $4.63 on Monday. The stock has a market capitalization of $2.41 billion, a price-to-earnings ratio of -2.60 and a beta of 0.93. The firm’s 50-day moving average price is $5.15 and its two-hundred day moving average price is $5.12. The company has a current ratio of 3.58, a quick ratio of 3.58 and a debt-to-equity ratio of 0.02. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.02. The firm had revenue of $5.18 million for the quarter, compared to analyst estimates of $19.36 million. Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The company’s revenue was down 80.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.34) EPS. On average, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on RXRX. Needham & Company LLC restated a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $7.25.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.